Skip to content
The Case for Keeping Orphans Where They Can Thrive episode artwork

Mar 23, 2016 15 min

The Case for Keeping Orphans Where They Can Thrive

from RARECast

Large pharmaceutical companies have grown increasingly interested in rare diseases, but acquisitions of rare disease companies by large biopharmaceutical companies may lead to a cultural mismatch that hinders the development and performance of their products. We spoke to Alain Gilbert, co-chairman of the global strategic consulting firm Bionest Parnters and co-author of a February 2016 analysis in In Vivo “Orphans Should Live Alone.” Gilbert discussed how small, rare disease-focused companies operate differently than large pharmaceutical companies, the essential role their relationship with patients play, and why big companies that acquire rare disease drug developers would be best to leave them alone.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

The Case for Keeping Orphans Where They Can Thrive

0:00 15:24

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 15 minutes long.

When was this RARECast episode published?

This episode was published on March 23, 2016.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.